Amgen And UCB Provide Update On Regulatory Status Of EVENITY In The US
Amgen and UCB announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY (romosozumab) as a…
Read More...
Read More...